PR Newswire

Brand Post December 7, 2024

New Data from PROMMIS Study Highlights the Power of SKY92 in Identifying High-Risk Multiple Myeloma Patients

ROTTERDAM, the Netherlands and SAN DIEGO, Dec. 7, 2024 /PRNewswire/ — SkylineDx, an innovative diagnostics company specializing in the research…

Brand Post December 7, 2024

Updated Results of Phase 3 ALLELE Study Presented at 66th American Society of Hematology Annual Meeting Confirm Efficacy, Safety and Durability of Novel Allogeneic Cell Therapy Tabelecleucel in Relapsed or Refractory Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD)

Tabelecleucel treated relapsed or refractory EBV+ PTLD patients achieved a 50.7% Objective Response Rate (ORR), 23.0-month Median Duration of Response (DOR), and Median Overall Survival (OS)…

Brand Post December 7, 2024

Blueprint Medicines’ Continued Leadership in Redefining the Standard of Care in Systemic Mastocytosis Highlighted at 2024 ASH Annual Meeting

— ASH data reinforce survival benefits of front-line AYVAKIT® (avapritinib) use in patients with advanced SM — — Bone density…

Brand Post December 7, 2024

Nektar Therapeutics Announces NKTR-255 Following CD19-directed CAR-T Therapy Enhanced Complete Response Rates in Patients with Relapsed or Refractory Large B-cell Lymphoma at the 66th Annual ASH Meeting

73% of the NKTR-255 treatment group compared to 50% of the placebo group achieved a complete response at 6 months…

Brand Post December 7, 2024

Ethara: YAS ALL IN: A WEEKEND OF RACING, ENTERTAINMENT, AND ADVENTURE ACROSS THE WHOLE OF ABU DHABI DURING GRAND PRIX WEEKEND

As the emirate continues to build its profile as a global sporting hub, ticket-holders can maximise their time in the…

Brand Post December 7, 2024

New Data from PROMMIS Study Highlights the Power of SKY92 in Identifying High-Risk Multiple Myeloma Patients

Updated Results of Phase 3 ALLELE Study Presented at 66th American Society of Hematology Annual Meeting Confirm Efficacy, Safety and Durability of Novel Allogeneic Cell Therapy Tabelecleucel in Relapsed or Refractory Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD)

Blueprint Medicines’ Continued Leadership in Redefining the Standard of Care in Systemic Mastocytosis Highlighted at 2024 ASH Annual Meeting

Nektar Therapeutics Announces NKTR-255 Following CD19-directed CAR-T Therapy Enhanced Complete Response Rates in Patients with Relapsed or Refractory Large B-cell Lymphoma at the 66th Annual ASH Meeting

Ethara: YAS ALL IN: A WEEKEND OF RACING, ENTERTAINMENT, AND ADVENTURE ACROSS THE WHOLE OF ABU DHABI DURING GRAND PRIX WEEKEND

CLASS ACTION AUTHORIZED AGAINST THE QUÉBEC MAJOR JUNIOR HOCKEY LEAGUE (QMJHL)¹ AND ITS TEAMS

TEDA Celebrates 40 Years of Pioneering Innovation, Inclusive Opening-up, and Synergistic development

ASPI Investors Have Opportunity to Lead ASP Isotopes Inc. Securities Fraud Lawsuit

A new layer of unique significance is attached to Spring Festival: Global Times editorial

SYM INVESTOR NOTICE: Symbotic Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit